Preview

Злокачественные опухоли

Расширенный поиск

АДЪЮВАНТНАЯ ТЕРАПИЯ БОЛЬНЫХ РАКОМ ТОЛСТОЙ КИШКИ II СТАДИИ — ТРУДНОЕ РЕШЕНИЕ ДЛЯ ХИМИОТЕРАПЕВТА

https://doi.org/10.18027/2224-5057-2019-9-3s1-15-22

Полный текст:

Аннотация

Несмотря на достижения хирургии и адъювантной химиотерапии показатели 5‑летней общей выживаемости пациентов с резектабельными стадиями рака толстой кишки остаются на уровне 60 %. И наиболее сложная в плане необходимости выбора адъювантной химиотерапии является II стадия заболевания. Поэтому изучение факторов, ассоциированных с прогнозом болезни, именно при II стадии рака толстой кишки, является актуальной задачей. За последние несколько лет выявлены новые прогностические факторы, получены данные о роли циркулирующей опухолевой ДНК в плазме крови при II стадии колоректального рака, представлены новые данные о возможности сокращения длительности адъювантной химиотерапии. Все это определило необходимость пересмотреть алгоритм выбора послеоперационного лечения при II стадии заболевания. Именно этому вопросу и посвящена настоящая статья.

Об авторе

М. Ю. Федянин
ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
Москва


Список литературы

1. https://www.uicc.org/news/new-global-cancer-dataglobocan-2018.

2. Oliphant R, Nicholson GA, Horgan PG, et al. Deprivation and colorectal cancer surgery: longer-term survival inequalities are due to differential postoperative mortality between socioeconomic groups. Ann Surg Oncol 2013;20:2132–9.

3. O'Connell JB, Maggard MA and Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96: 1420 1425, 2004.

4. O'Connor ES, Greenblatt DY, LoConte LK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Onc. 2011;29:3381–3388.

5. IMPACT B2 Investegators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer: International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17:1356–1363, 1999.

6. Gill S, Loprinzi CL, Sargent DJ , et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797–1806, 2004.

7. Figueredo A, Charette ML, Maroun J, et al: Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidencebased care»s gastrointestinal cancer disease site group. J Clin Oncol 22:3395–3407, 2004.

8. Quasar Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020–2029, 2007.

9. Shi Q, Andre T, Grothey A, et al: Comparison of outcomes after fluorouracilbased adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: Evidence of stage migration from the ACCENT database. J Clin Oncol 31:3656–3663, 2013.

10. Matsuda C, Ishiguro M, Teramukai S, et al. A randomised-controlled trial of 1‑year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer. 2018 Jun;96:54–63.

11. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–994.

12. Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004 Aug 15;22 (16):3408–19.

13. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27 (19):3109–3116.

14. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29 (28):3768e3774.

15. Schmoll H-J, Tabernero J, Maroun A, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5‑fluorouracil / leucovorin (5‑FU / LV) as adjuvant therapy for stage III colon cancer: survival follow-up of study NO16 968 (XELOXA). J Clin Oncol 2012;30

16. (Suppl. 4):388.

17. Tournigand C, Andr_e T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial. J Clin Oncol 2012;30 (27): 3353–3360.

18. André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10‑Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015 Dec 10;33 (35):4176–87.

19. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007;25 (16): 2198e2204.

20. Twelves C, Wong A, Nowacki MP. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696–704.

21. Lembresky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from NSABP protocol C-06. J Clin Oncol 2006;24:2059–64.

22. Saini A, Norman AR, Cunningham D, et al. Twelve weeks of protracted venous infusion of fluorouracil is as effective as 6 months of bolus 5 FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;16:1859–65.

23. Carrato A, Kohne C, Bedenne L, et al. Folinic acid modulated bolus 5 FU or infusional 5 FU adjuvant treatment of patients of UICC stage III colon cancer: preliminary analysis of the PETACC 2 study. Proc ASCO 2006;24:18s

24. Sougklakos I, Boukovinas I, Xynogalos S, et al. Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. J Clin Oncol 37, 2019 (suppl; abstr 3500).

25. Iveson T, Sobrero AF, Yoshino T, et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). J Clin Oncol 37, 2019 (suppl; abstr 3501).

26. de Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: French intergroup study. J Clin Oncol 15:808–815, 1997.

27. Федянин М.Ю. Современная клиническая и молекулярно-генетическая платформа лечения больных раком толстой кишки. Диссертация доктора медицинских наук. Москва. 2018.

28. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon//Science 1993;260:816–819.

29. Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer// Br J Cancer 2009;100: 266–73.

30. Gryfe R, Kim H, Hsieh ETK, et al. Tumour microsatellite instability and clinical outcome in young patients with colorectal cancer//N Engl J Med 2000;342:69–77.

31. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracil based adjuvant chemotherapy for colon cancer//N Engl J Med 2003;349:247–57.

32. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis . J Clin Oncol 2005;23:609–18.

33. Roth AD, Tejpar S, Yan P, et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3– EORTC 40 993 — SAKK 60–00 trial.J Clin Oncol (meeting abstract) 2009;27:4002.

34. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the gene in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009;25 (15 Suppl): 169s.

35. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5‑fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365–73.

36. des Guetz G, Schischmanoff O, Nicolaset P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer.2009; 45:1890–1896.

37. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a metaanalysis of colorectal cancer survival data. Eur. J. Cancer.2010; 46: 2788–2798.

38. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for determination of microsatellite instability in colorectal cancer//Cancer Res. 1998;58 (22):5248–57.

39. Gaustadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Micrisatellite instability as a marker of prognosis and response to therapy: metaanalysis of colorectal cancer survival data//Eur J Cancer. 2010;46 (15):2788–98.

40. Des Guets G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis//Eur J Cancer. 2009;45 (10):1890–6.

41. Crowley E, Di NF, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472–84.

42. Tie J, Wang Y, Kinde I, et al. Circulating tumor DNA (ctDNA) in nonmetastatic colorectal cancer (CRC): Potential role as a screening tool. J Clin Oncol. 2015;33 (s3):abstr. 518.

43. Taieb J, Taly V, Vernerey D, et al. Analysis of circulating tumor DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. Annals of Oncology (2019) 30 (suppl_5): v851‑v934.


Для цитирования:


Федянин М.Ю. АДЪЮВАНТНАЯ ТЕРАПИЯ БОЛЬНЫХ РАКОМ ТОЛСТОЙ КИШКИ II СТАДИИ — ТРУДНОЕ РЕШЕНИЕ ДЛЯ ХИМИОТЕРАПЕВТА. Злокачественные опухоли. 2019;9(3s1):15-22. https://doi.org/10.18027/2224-5057-2019-9-3s1-15-22

Просмотров: 146


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2224-5057 (Print)
ISSN 2587-6813 (Online)